The objective of the current study is to investigate the efficacy safety and tolerability of BI 10773 10 mg 25 mg once daily compared to placebo given for 24 weeks as add-on therapy to metformin or metformin plus sulfonylurea in patients with T2DM with insufficient glycaemic control
Data and Resources
- A phase III randomised double-blind placebo-controlled parallel group efficacy and safety study of BI 10773 10 mg 25 mg administered orally once daily over 24 weeks in patients with type 2 diabetes with insufficient glycaemic control despite...json
The objective of the current study is to investigate the efficacy safety and...
|Release Date|| |
License Not Specified
|Public Access Level|| |